Consideraţii de actualitate privind rolul histeroscopiei în diagnosticul şi tratamentul adenomiozei la pacientele infertile

 Actual considerations concerning the contribution of histeroscopy to diagnosis and treatment of adenomyosis in infertile patients

First published: 20 septembrie 2019

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Gine.25.3.2019.2496


Introduction and objective. A classical histological de­fi­nition for adenomyosis is the invasion of the gland or endometrial stroma miometer, more than 2,5 mm from the junctional area, accompanied by the adja­cent mus­cu­lar tissue hyperplasia. Adenomyosis is a gyne­co­lo­gical pathology commonly found in women of re­pro­ductive age and is a frequent cause of infertility. Hys­te­ro­scopy is not the primary diagnostic and thera­peutic method for ade­no­myo­sis, but may be useful in some cases. Metho­do­logy. This pa­per is a systematic review of the literature which aims to highlight the role of hysteroscopy in the diagnosis and treatment of adenomyosis in infertile patients. Results. Hys­teroscopy is a useful therapeutic and diagnostic method for infertile patients with adenomyosis, as many specialized studies show. Conclusions and discussion. Hys­teroscopy is a useful method of diagnosis and treatment only in well-selected cases of focal and diffuse superficial adenomyosis. Exploring the uterus should not be limited to hysteroscopy in infertile patients with adenomyosis.

adenomyosis, hysteroscopy, infertility, IVF, ICSI


Introducere şi obiectiv. O definiţie histologică clasică pen­tru adenomioză este invazia miometrului de glande sau stro­mă endometrială mai mult de 2,5 mm de la nivelul zonei jonc­ţio­na­le, acompaniată de hiperplazia ţesutului muscular adia­­cent. Adenomioza este o patologie ginecologică frecvent în­tâl­­nită la femeile de vârstă reproductivă şi este o cauză frec­ven­tă de infertilitate. Histeroscopia nu este principala metodă diag­nos­ti­că şi terapeutică în cazul adenomiozei, dar poate fi utilă în anu­mi­te cazuri. Metodologie. Lucrarea de faţă este un review sis­te­ma­tic al literaturii de specialitate, cu scopul de a evidenţia ro­lul histeroscopiei în diagnosticul şi tratamentul adenomiozei la pacientele infertile. Rezultate. Histeroscopia este o metodă uti­lă atât terapeutică, cât şi diagnostică la pacientele infertile cu ade­no­mioză, aşa cum arată numeroase studii de specialitate. Concluzii şi discuţie. Histeroscopia este o metodă utilă de diagnostic şi tratament doar în cazuri bine selecţionate de adenomioză focală şi difuză superficială. Explorarea uterului nu ar trebui să se limiteze doar la histeroscopie în cazul pacientelor infertile cu adenomioză. 


In 1860, Karl Freiherr von Rokitansky described adenomyosis as a “fibrous tumor containing gland similar to endometrial glands”(1). The current definition of adenomyosis is “benign pathology of the uterus characterized by the invasion of the myometrium by endometrial and stromal glands”(2). The most common symptoms that patients present with are: dysmenorrhea, menometroragies, infertility, and dyspareunia. One third of women diagnosed with adenomyosis are however asymptomatic(3).

Adenomyosis is commonly diagnosed over the age of 40 years(4). More and more women postpone the moment of conception until 35 years old(5). This is relevant in the context of the adenomyosis in patients who desire a pregnancy(6). Improving diagnostic imaging methods allows the detection of adenomyosis in a significant proportion of previously diagnosed patients with unknown infertility(7). Since radical surgery is not an option for pregnant women with adenomyosis, many minimally invasive medical and surgical treatments are proposed and compete to prove their primacy in the treatment of adenomyosis in infertile patients(8,9). Hysteroscopy is a diagnostic and therapeutic option for infertile patients, strongly under debate in recent years in terms of efficacy in patients with adenomyosis who wish to achieve a pregnancy and with repeated implantation failures(10).

What is adenomyosis?

A definition of adenomyosis still valid today dates back to 1972, when Bird et al. described this pathology as a “benign invasion of the myometrium by the endometrium, which produces diffuse enlargement of the uterus and is explained microscopically by the presence of endometrial glands and stoma surrounded by adjacent myometrial hypertrophy”. The thickness of the invasion is another important aspect of the definition(11).

When the physiologic barrier of endometrial basal layer and myometrium is exceeded, the myometrium is invaded by endometrial glands that give birth to ectopic intra-myometrial glands. The result of this invasion is hypertrophy and adjacent myometrial hyperplasia(12).

Usually, the diagnosis of adenomyosis is based on the histological outcome. This is particularly possible following examination of the parts resulting from total hysterectomy. It was initially believed that adenomyosis is diagnosed exclusively in multiparous patients(13). In about 80% of cases, adenomyosis is present simultaneously with endometriosis and uterine fibroids(14,15). The incidence of adenomyosis varies between 5% and 38.5% in the literature. This variation depends on the diagnosis method(11,16). The prevalence of adenomyosis varies in the literature between 10% and 90%(17-20).

The prevalence of adenomyosis is dependent on age, parity, and association with endometriosis(20). The accurate prevalence of adenomyosis in patients with infertility is more difficult to assess because most prevalence studies come from elderly women after hysterectomy. Moreover, most existing studies show the prevalence of adenomy­osis in symptomatic patients(19). For example, the prevalence of adenomyosis in patients with dysmenorrhea is approximately 53%(13,21). The prevalence of adenomyosis is estimated to be about 30-40% in infertile women using assisted human reproductive techniques. The negative effect of adenomyosis in terms of in vitro fertilization (IVF) results is well known(22,23).

Risk factors for adenomyosis

As mentioned before, adenomyosis frequently coexists with other gynecological disorders and is more common in women in the fifth decade of age(5).

A study on 160 women showed a higher frequency in multiparous patients, in patients with at least one spontaneous abortion or having a cervical curettage, in smokers and in irregularly-menstrual cycle patients.

The explanation for the association of adenomyosis with multiparity could be the trophoblastic invasion of the myometrium during pregnancy. There are many controversies about caesarean section and adenomyosis(4,24,25).

Other studies support the impact of sex hormones on the etiology of adenomyosis: the presence of estrogen receptors, along with various progesterone receptors and androgens receptors in adenomyotic tissue. It seems that the number of progesterone receptors would be higher than of estrogenic ones(26,27). In terms of smoking, some authors claim that it is a risk factor for adenomyosis (especially smoking for over 10 years)(24), while other authors claim that smoking is a protective factor for adenomyosis by lowering estrogen levels in the blood of smoking patients(4). Vercellini includes endometriosis and surgical procedures (both uterine curettage and caesarean section) among the risk factors associated with the presence of adenomyosis(12).

Adenomyosis classification

There are many proposed classifications of adenomyosis, but there isn’t a complete one that takes into consideration all of the below aspects.

Histologically, based on the extent of the lesions, Charles et al. divides the adenomyosis into three grades as following:

  • Grade I – sub-basal endometrial stratum.

  • Grade II – up to mid-myometrium.

  • Grade III – beyond mid-myometrium(28).

G. Kunz et al., in 2007, classified adenomyosis based on the thickness of junctional zone (JZ) on MRI (Magnetic Resonance Imaging):

  • Hyperplasia of JZ – 8-12 mm (partial or diffuse).

  • Adenomyosis – >12 mm (could involve the outer myometrium; several high-signal intensity foci in the myometrium).

  • Adenomyomas – several masses within the myometrium with no visible margins of primarily low-signal (could involve the fallopian tube, the bladder; retro-cervical or retro-vaginal)(29).

Based on the disease localization, Y. Kishi et al. finds four subtypes of adenomyosis and classifies them based on MRI specification: intrinsic, extrinsic, intramural and indeterminate(30).

Based on both histological and clinical criteria, for choosing the optimal surgical treatment, Gordts et al. classifies the adenomiotic lesions as follows:

  • Diffuse – JZ thickening and extension of endometrial glands in the outer myometrium.

  • Focal – adenomyotic masses/cysts within the myometrium.

  • Polypoid adenomyomas (both typical and atypical).

  • Adenomyosis of the cervix.

  • Retroperitoneal adenomyosis(31).

The junctional zone (JZ) definition

Even though the uterine myometrium is considered an assemblage of homogenous smooth muscle fibers, there are MRI findings describing two different zones within. The first one is the junctional zone which can be considered the sub-endometrial myometrium and the second one the outer myometrium. There are significant functional and structural differences between the two of them. A diffuse thickening of the junctional zone is believed to be a distinctive feature of adenomyosis and consists of a disarrangement of smooth muscle fibers(32)

This JZ is thought to be the imaging component, the “myosis”, while the histological component is the invasiveness of the endometrial glands in the myometrium, the “adeno”.

Therefore, the JZ myometrium is much more related to the endometrium than the outer part of the myometrium. Like the former one, it is from müllerian origins and depends on the hormone variations dependent on the menstrual cycle. Also, both the endometrium and the JZ myometrium reach a maximum growth between days 8 and 16 of menstrual cycle and play a key role in implantation and placentation by trophoblast invasion(33).

Adenomyosis and infertility

Numerous studies have shown that adenomyosis is associated with decreased results following assisted reproduction techniques (ART), FIV/ICSI (in vitro fertilization/ intracytoplasmic sperm injection) in terms of decreasing implantation rate, increased risk of spontaneous abortion, decreasing live birth rates(6,22,33,34). A study of 345 patients who performed PGS (Preimplantation Genetic Screening) showed the association of adenomyosis with an increased rate of early spontaneous abortion independent of maternal age and genetic quality of the embryo(35). A meta-analysis that included six studies and nearly 10,000 patients showed increased risk of premature birth, premature rupture of membranes, low birth weight, spontaneous abortion and preeclampsia in adenomyosis women compared to women without this pathology. The same study demonstrates that there is no correlation between adenomyosis and an abnormal fetal presentation(36).

How does adenomyosis influence fertility?

The fact that adenomyosis affects pregnancy rate is described by numerous studies, but the mechanisms by which fertility is affected are strongly still under debate(37-40).

One of the mechanisms by which adenomyosis could affect embryo implantation in patients with adenomy­osis is explained by K.P. Tremellen and P. Russell. A higher density of macrophages and killer cells in the endometrial stroma was observed in patients with diffuse adenomyosis or localized adenomyoma(41). Brosens et al. explains the negative influence of adenomyosis in IVF cycles by increasing local estrogen production due to overexpression of P450 aromatase(42). Modification of utero-tubal peristalsis and impaired sperm transport were explained as a mechanism of infertility in adenomyosis by S. Kissler et al. in 2006. This mechanism is particularly valid in the presence of diffuse adenomyosis in the patients with normal tube-ovarian anatomy(43).

The inflammatory reaction produced by prostaglandins and cytokines also causes damage to uterine peristalsis and damages sperm transport(44). The formation of free radicals affecting the oocytes and the embryos is explained by another study. Ota et al. states the expression of antigens at the surface of endometrial cells in patients with adenomyosis, which results in an increase number of macrophages and immune cells that result in immunoglobulin and complement deposition. Also, immune cells activate secreted cytokines that affect the quality of oocytes and embryos in patients with adenomyosis(45).

The decrease in endometrial sensitivity is explained by several mechanisms, as follows. The first mechanism is the presence of increased amounts of free radicals that attempt to explain how adenomyosis affects fertility(46). Leukemia inhibitor factor and interleukin 11 levels have been shown to be higher in infertile patients with adenomyosis. This is also incriminated in decreasing endometrial receptivity(47). Another mechanism that explains repeated implantation failure in women with adenomyosis is the lower LIF (Leukemia Inhibitory Factor) expression in the secretory phase in women with adenomyosis(48).

How does adenomyosis influence the FIV/ICSI results?

Numerous studies show that adenomyosis reduces the rate of implantation, the number of embryos transferred and the rate of pregnancy in patients following IVF cycles(18,38). Other authors recommend screening for adenomyosis before starting assisted human reproduction procedures. The role of this recommendation is to be able advising patients about the prognosis of the procedure in the presence of adenomyosis. A recent study included nearly 1,000 patients who were divided into three groups depending on the presence or absence of adenomyosis and endometriosis. Clinical pregnancy rate has always been lower in the presence of adenomyosis. The rate of spontaneous abortion was 35% and 40% in adenomyosis patients compared with patients without pathology or in endometriosis patients without adenomyosis(49). A meta-analysis from 2017 showed the same result: the implantation rate, the pregnancy rate per cycle and per embryo transfer, and the live birth rate in women with adenomyosis are significantly lower than in women without adenomyosis(22). A. Hashimoto et al. emphasize that adenomyosis is associated with a higher risk of abortion in the second trimester of pregnancy, as well as a lower risk of adverse placental positioning(50).

Diagnosis and treatment of adenomyosis in infertile patients

Adenomyosis in infertile patients can be treated surgically or medically. Since effective therapeutic options are limited when it comes to preserving fertility in infertile patients with adenomyosis, we will only review the appropriate therapeutic options.

Surgical excision is indicated for patients seeking a pregnancy in case of focal adenomyosis or in the presence of adenomyomata. GnRH agonists (Gonadotropin-Releasing Hormone; GnRHa) have a proliferative effect on tissues, induce apoptosis and reduce inflammation and angiogenesis(8). Surgery in patients with adenomyosis and infertility should be considered in symptomatic women with repeated failure of implantation. Moreover, surgery increases the risk of uterine rupture(9).

As mentioned before, focal adenomyosis can be excised more easily than diffuse adenomyosis which is more severe and more difficult to manage(51,52). However, there are authors who support the effectiveness of surgery in treating diffuse adenomyosis(52). Instead of surgical treatment, the treatment with GnRH agonists is less invasive and easier(8). The utility of GnRH agonists for adenomyosis, as well as their effect on fertility are suggested by numerous studies showing an increase in the rate of clinical pregnancies following embryo transfer with frozen embryos(53-56). The treatment with GnRH agonists decreases the size of adenomyotic lesions and has a positive effect on implantation markers(56). In addition to the many advantages of using GnRH agonists, it seems that the disadvantages of using them are: higher doses of gonadotrophins required for ovarian stimulation and a higher number of stimulation days within IVF cycles(22).

Margit Dueholm and Jørn Aagaard recommend women with adenomyosis and repeated implantation failures to address specialized centers for the treatment of adenomyosis or research(57).

What is the role of ultrasonography and MRI in the diagnosis of adenomyosis?

The diagnosis of adenomyosis in recent years can be determined both by transvaginal ultrasound and by MRI. Ultrasound diagnosis is possible with technological improvement. 3D (three-dimensional) ultrasound allows a more accurate assessment of the junctional area, as well as a precise description of certain features of adenomyosis(58-64).

Adenomyosis is more and more common in women with infertility or subfertility, and both transvaginal ultrasound and MRI are non-invasive diagnostic tools similar in accuracy(19). A meta-analysis from 2018 showed that 2D transvaginal ultrasound had a specificity of 63.9% and a sensitivity of 83.8% in the diagnosis of adenomyosis, while transvaginal 3D ultrasound had a specificity of 56% and a sensitivity of 88.9%(62). The Morphological Uterus Sonographic Assessment (MUSA) group developed in 2015 a system of uterine assessment criteria that allowed the diagnosis of adenomyosis to be made easier by certain standard characteristics: asymmetric thickening of the uterine wall, hypoechoic intramural cysts or hypoechoic islands tissue, the appearance of some shadows, sub-endometrial echoic lines, interruption of the junctional area etc(63).

MRI assessment is considered as gold standard in the evaluation of adenomyosis(19), but other authors show good correlation and good agreement between MRI and transvaginal ultrasound(56). Moreover, ultrasonography has the advantage of a lower cost and is more affordable than MRI(66). The diagnosis of adenomyosis by MRI is especially related to the thickening of the junctional area(67,68). The most common features of adenomyosis seen in MRI, in addition to thickening of the junctional area, are: the presence of an enlarged asymmetric uterus, in the absence of uterine fibroids and high-intensity myometrial outbreaks in T1(7,69,70). The MRI sensitivity in adenomyosis detection is 77% and the specificity is 89%, according to a recent study from 2018(71).

What is the role of histeroscopy in the diagnosis and the treatment of adenomyosis in infertile patients?

Currently, hysteroscopy is an indispensable diagnostic tool in the field of infertility. According to some authors, hysteroscopy is not a gold standard in assessing the uterine cavity in infertile patients before starting assisted human reproductive procedures(72). However, many infantile specialists do not start an IVF cycle without the patient having performed a diagnostic hysteroscopy(73-75).

Starting with 2008, some studies support the use of hysteroscopy as a routine in evaluating infertility, as there is an increased incidence of intrauterine pathologies in infertile patients(76). Diagnostic hysteroscopy in asymptomatic women before the first IVF cycle is considered a safe procedure and has been associated with an increased chance of getting a pregnancy(77). Hysteroscopy allows the direct visualization of the uterine cavity. Hysteroscopy with vaginoscopy allows the visualization of the uterine cavity in an atraumatic manner, without the need for a speculum that is difficult to tolerate for the patient(78,79). The exploration of the uterus by hysteroscopy is limited to the uterine cavity and pathology associated with the endometrium. The exploration of the underlying myometrium can be done using the trophiscope that allows the extraction of endometrial biopsy(31). Hysteroscopy exploration of the underlying myometrium may focus on the diagnosis of adenomyosis when there are specific signs such as neovascularization, endometriosis implants, or adenomyotic cysts(80).

Regarding the hysteroscopy diagnosis of adenomyosis, certain signs and aspects are suggestive: the irregular endometrium with small geodes, the accentuation of the vascularization, the “strawberry pattern” of the endometrium, the small fibrous cysts, the chocolate cysts that through transparency are colored in blue or brown-chocolate(81).

Hysteroscopy treatment of adenomyosis is indicated in well-selected cases and in patients who desire to preserve fertility, and aims to remove adenomyotic tissue entirely without affecting healthy adjacent muscle tissue(82,83).

Hysteroscopy allows the enucleation of focal or cystic adenomyosis by means of the bipolar strand. The technique is similar to the one used for hysteroscopy myomectomies (slicing), the difference being that in the case of adenomyosis there is no capsule showing the resection limit(78,84). If the nodule is implanted deeper, the hydro massage technique by juggling with intra-cavity pressures leads to its migration closer to the cavity and easy access for resection(85).

Diffuse adenomyosis cannot benefit from hysteroscopy resection(86). In the case of diffuse superficial adenomyosis, the incisions of several millimeters can be made by means of the monopolar needle. This is a backup solution that is not documented and can be useful as a backup technique for patients with quality blastocysts and multiple implant failures where classic surgical methods and therapeutic methods have not proven effective.


Transvaginal ultrasound and MRI exploration are two non-invasive diagnostic tests and extremely useful in the diagnosis of adenomyosis, having similar sensitivity and specificity. Diagnostic hysteroscopy performed routinely in asymptomatic women before starting an in vitro fertilization cycle is associated with a higher pregnancy rate and a higher live births rates. The negative effect of adenomyosis on pregnancy rate in patients seeking a pregnancy and appealing to assisted human reproductive techniques is well known, and the use of the long-acting GnRH antagonist protocol appears to be beneficial in these patients. Hysteroscopy is a useful therapeutic and diagnostic method for infertile patients with adenomyosis, as many specialized studies show. Hystero­scopy is a useful method of diagnosis and treatment only in well-selected cases of cystic, focal and superficial diffuse adenomyosis. Exploring the uterus should not be limited to hysteroscopy in infertile patients with adenomyosis.  

Conflict of interests: The authors declare no conflict of interests.


  1. Rokitansky C. Uber uterusdrusen-neubildung in uterus und ovarial-sarcomen. Zeitschr Gesellschaft der Aerzte Wien. 1860; 16:577–81.
  2. McCluggage WG, Robboy SJ. Mesenchymal uterine tumors, other than pure smooth muscle neoplasms, and adenomyosis. In: Robboy SJ, Mutter GL, Prat J, et al, editor. Robboy’s pathology of the female reproductive tract (2nd ed) Churchill Livingstone Elsevier, London, UK.2009; 427–56.
  3. Peric H, Fraser IS. The symptomatology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4):547–55.
  4. Taran FA, Stewart EA, Brucker S. Adenomyosis: Epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd. 2013; 73(9):924–31.
  5. Mac Dougall K, et al. Age shock: misperceptions of the impact of age on fertility before and after IVF in women who conceived after age 40. Hum Reprod. 2013; 28(2):350–6.
  6. Buggio L, et al. Adenomyosis: fertility and obstetric outcome. A comprehensive literature review. Minerva Ginecol. 2018;70(3):295-302. 
  7. Bazot M, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod. 2001; 16(11):2427-33.
  8. Khan KN, et al. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod. 2010;25:2878–90.
  9. Tsui KH, et al. Conservative surgical treatment of adenomyosis to improve fertility: controversial values, indications, complications, and pregnancy outcomes. Taiwan J Obstet Gynecol. 2015; 54(6):635–40.
  10. Di Spiezio Sardo A, et al. The role of hysteroscopy in the diagnosis and treatment of adenomyosis. Biomed Res Int. 2017; 1–7.
  11. Bird C, McElin T, Manalo-Estrella P. The elusive adenomyosis of the uterus – revisited. Am J Obstet Gynecol. 1972; 112:583e593.
  12. Vercellini P, Viganò P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Clin Obstet Gynaecol. 2006; 20:465–77.
  13. Kissler S, et al. Duration of dysmenorrhoea and extent of adenomyosis visualised by magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol. 2008; 37:204–9.
  14. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4):511–21.
  15. Aleksandrovych V, et al. Uterine fibroid: common features of widespread tumor (Review article). Folia Med Cracov. 2015; 55(1):61–75.
  16. Gambone JC, et al. Validation of hysterectomy indications and the quality assurance process. Obstet Gynecol. 1989; 73(6):1045-9.
  17. Yeniel O, Cirpan T, Ulukus M, et al. Adenomyosis: prevalence, risk factors, symptoms and clinical findings. Clin Exp Obstet Gynecol. 2007; 34:163–7.
  18. Vercellini P, et al. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod. 2014; 29(5): 964 -77.
  19. Maheshwari A, et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012; 18(4):374 -92.
  20. Naftalin J, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012; 27(12):3432-9. 
  21. De Souza NM, et al. The potential value of magnetic resonance imaging in infertility. Clin Radiol. 1995; 50:75–9.
  22. Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017; 108:483–90.e3.4.
  23. Li X, Liu X, Guo SW. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. J Obstet Gynaecol Res. 2014; 40: 485–94.
  24. Shrestha A. Risk factors for adenomyosis. J Nepal Health Res Counc. 2012; 10(22):229-33.
  25. Romanek K, et al. Risk factors for adenomyosis in patients with symptomatic uterine leiomyomas. Ginekol Pol. 2010; 81(9):678–80. 
  26. Kitawaki J. Adenomyosis: The pathophysiology of an estrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4):493–502.
  27. Levy M, et al. Differential expression of selected gene products in uterine leiomyomata and adenomyosis. Fertil Steril. 2007; 88(1):220–3.
  28. Charles C, et al. The elusive adenomyosis of the uterus-revisited. AJOG. 1972; 112(5):583-93.
  29. Kunz G, et al. Adenomyosis as a disorder of the early and late human reproductive period. Reprod BioMed Online. 2007; 15(6):681–5.
  30. Kishi Y, et al. Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification. Am J Obstet Gynecol. 2012; 207(2):114.e1-7.
  31. Gordts S, et al. Symptoms and classification of uterine adenomyosis, including the place of histeroscopy in diagnosis. Fertil Steril. 2018 Mar; 109(3):380-388.e1.
  32. Brosens JJ, de Souza NM, Barker FG. Uterine junctional zone: function and disease. Lancet. 1995; 346(8974):558-60.
  33. Gordts S, et al. Uterine adenomyosis: a need for uniform terminology and consensus classification. Reprod BioMed. 2008; 17(2):244-8. 
  34. Kuijsters NPM, et al. Uterine peristalsis and fertility: current knowledge and future perspectives: a review and meta-analysis. Reprod Biomed Online. 2017; 35(1):50-71.
  35. Stanekova V, Woodman RJ, Tremellen K. The rate of euploid miscarriage is increased in the setting of adenomyosis. Hum Reprod Open. 2018; 2018(3):hoy011.
  36. Razavi M, et al. Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. Int J Gynaecol Obstet. 2019; 145(2):149-57.
  37. Yan L, et al. Effect of adenomyosis on in vitro fertilization/intracytoplasmic sperm injection outcomes in infertile women: a retrospective cohort study. Gynecol Obstet Invest. 2014; 77:14–8.
  38. Salim R, et al. Adenomyosis reduces pregnancy rates in infertile women undergoing IVF. Reprod Biomed Online. 2012; 25:273–7.
  39. Benaglia L, et al. Asymptomatic adenomyosis and embryo implantation in IVF cycles. Reprod Biomed Online. 2014; 29:606–11.
  40. Costello MF, Lindsay K, McNally G. The effect of adenomyosis on in vitro fertilisation and intra-cytoplasmic sperm injection treatment outcome. Eur J Obstet Gynecol Reprod Biol. 2011; 158:229–34.
  41. Tremellen KP, Russell P. The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. II: adenomyosis and macrophages. J Reprod Immunol. 2012; 93(1):58-63. 
  42. Brosens J, et al. High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome. Hum Reprod. 2004; 19(2):352-6.
  43. Kissler S, et al. Uterotubal transport disorder in adenomyosis and endometriosis - a cause for infertility. BJOG. 2006; 113(8):902-8.
  44. Harada T, et al. The impact of adenomyosis on women’s fertility. Obstet Gynecol Surv. 2016; 71(9):557–68.
  45. Ota H, et al. Is adenomyosis an immune disease? Human Reprod Update. 1998; 4(4):360-7.
  46. Campo S, et al. Infertility and adenomyosis. Obstet Gynecol Int. 2012; 2012:786132.
  47. Mikolajczyk M, Wirstlein P, Skrzypczak J. Leukaemia inhibitory factor and interleukin 11 levels in uterine flushings of infertile patients with endometriosis. Hum Reprod. 2006; 21(12):3054–8.
  48. Xiao Y, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril. 2010; 94(1):85–9.
  49. Sharma S. Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. Reprod Biomed Online. 2019; 38(1):13-21.
  50. Hashimoto A, et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. J Matern Fetal Neonatal Med. 2018; 31(3):364-9.
  51. Al Jama FE. Management of adenomyosis in subfertile women and pregnancy outcome. Oman Med J. 2011; 26:178–81. 
  52. Wang PH, et al. Is the surgical approach beneficial to subfertile women with symptomatic extensive adenomyosis? J Obstet Gynaecol Res. 2009; 35:495–502. 
  53. Hirata JD, Moghissi KS, Ginsburg KA. Pregnancy after medical therapy of adenomyosis with a gonadotropin-releasing hormone agonist. Fertil Steril. 1993; 59:444–5.
  54. Niu Z, et al.Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol. 2013; 29:1026–30.
  55. Park CW, et al. Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clin Exp Reprod Med. 2016; 43:169–73.
  56. Khan KN, et al. Decreased expression of human heat shock protein 70 in the endometria and pathological lesions of women with adenomyosis and uterine myoma after GnRH agonist therapy. Eur J Obstet Gynecol Reprod Biol. 2015; 187:6–13.
  57. Dueholm M, Aagaard J. Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations. Expert Rev Endocrinol Metab. 2018;13(4):177-9.
  58. Dueholm M. Transvaginal ultrasound for diagnosis of adenomyosis: a review. Best Pract Res Clin Obstet Gynaecol. 2006; 20:569–82.
  59. Meredith SM, Sanchez-Ramos L, Kaunitz AM. Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and meta-analysis. Am J Obstet Gynecol. 2009; 201:107–12.
  60. Luciano DE, et al. Three-dimensional ultrasound in diagnosis of adenomyosis: histologic correlation with ultrasound targeted biopsies of the uterus. J Minim Invasive Gynecol. 2013; 20:803–10.
  61. Exacoustos C, et al. The uterine junctional  zone: a 3-dimensional ultrasound study of patients with endometriosis. Am J Obstet Gynecol. 2013; 209(3):248.e1–7.
  62. Andres MP, et al. Transvaginal ultrasound for the diagnosis of adenomyosis: systematic review and meta-analysis. J Minim Invasive Gynecol. 2018; 25:257–64.
  63. Van den Bosch T, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015; 46:284–98.
  64. Brătilă E, et al. Diagnosis of endometriotic lesions by sonovaginography with ultrasound gel. Medical Ultrasonography. 2016; 18(4):469-74.
  65. Genc M, Genc B, Cengiz H. Adenomyosis and accompanying gynaecological pathologies. Arch Gynecol Obstet. 2014; 4:877–81.
  66. Reid S et al. Prediction of pouch of Douglas obliteration in women with suspected endometriosis using a new real-time dynamic transvaginal ultrasound technique: the sliding sign. Ultrasound Obstet Gynecol. 2013; 41:685–91.
  67. Exacoustos C, Manganaro L, Zupi E. Imaging for the evaluation of endometriosis and adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2014; 28(5):655–81. 
  68. Maubon A, et al. Uterine junctional zone at magnetic resonance imaging: a predictor of in vitro fertilization implantation failure. J Obstet Gynaecol Res. 2010; 36:611–8.
  69. Reinhold C, et al. Uterine adenomyosis: endovaginal US and MR imaging features with histopathologic correlation. Radiographics. 1999; 19 Spec No:S147-160.
  70. Bragheto AM, et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007; 76(3):195-9.
  71. Bazot M, Daraï E. Role of transvaginal sonography and magnetic reso­nance imaging in the diagnosis of uterine adenomyosis. Fertil Steril. 2018;109(3):389–97. 
  72. Smit JG, et al. Hysteroscopy before in-vitro fertilisation (inSIGHT): a multicentre, randomised controlled trial. Lancet. 2016; 387:2622–9.
  73. Shohayeb A, El-Khayat W. Does a single endometrial biopsy regimen (S-EBR) improve ICSI outcome in patients with repeated implantation failure? A randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2012; 164:176–9.
  74. Surrey ES. Should diagnostic hysteroscopy be performed before in vitro fertilization-embryo transfer? J Minim Invasive Gynecol. 2012; 19(5):643-6.
  75. Bosteels J, et al. The effectiveness of hysteroscopy in improving pregnancy rates in subfertile women without other gynaecological symptoms: a systematic review. Hum Reprod Update. 2010; 16(1):1-11.
  76. Lorusso F. et al. Office hysteroscopy in an in vitro fertilization program. Gynecol Endocrinol. 2008; 24(8):465–9.
  77. Pundir J, et al. Hysteroscopy prior to the first IVF cycle: A systematic review and meta-analysis. Reprod  BioMed Online. 2014; 28(2):151-61.
  78. Molinas CR,  Campo R. Office hysteroscopy and adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006; 20:557–67.
  79. Bettocchi S. Office hysteroscopy. Obstet Gynecol Clin North Am. 2004; 31(3):641-54, xi.
  80. Puttemans P, et al. Hysteroscopic  images of an isolated lesion of unknown origin in a young infertile patient. J Minim Invasive Gynecol. 2005; 12:104–5.
  81. Nappi C, Di Spiezio Sardo A. Rare and difficult-tointerpret hysteroscopic findings. In: State-of-the-Art Hysteroscopic Approaches to Pathologies of the Genital tract, Nappi C, Di Spiezio Sardo A, Eds. Endo-Press, Tuttlingen, 2014; 236–49.
  82. Levgur M. Therapeutic options for adenomyosis: A review. Arch Gynecol Obstet. 2007; 276(1):1–15.
  83. Keckstein J. Hysteroscopy and adenomyosis. Contributions to Gynecology and Obstetrics. 2000; 20:41–50.
  84. Gordts S, Campo R, Brosens I. Hysteroscopic diagnosis and excision of myometrial cystic adenomyosis. Gynecol Surg. 2014;11(4):273–8.
  85. Zayed M, et al. Hysteroscopic myomectomy of large submucous myomas in a 1-step procedure using multiple slicing sessions technique. J Minim Invasive Gynecol. 2015; 22(7):1196-202.
  86. McCausland V, McCausland A. The response of adenomyosis to endometrial ablation/resection. Hum Reprod Update. 1998; 4(4):350–9.

Articole din ediţiile anterioare

GINECOLOGY | Ediţia 1 23 / 2019

Recurenţa polipilor endometriali – factori de risc şi tratament

E.A. Bordea, M. Cosma, R. Dragomir, A. Carp-Velişcu, Bogdan Marinescu, Prof. Dr. Elvira Brătilă

Polipii endometriali (PE) sunt frecvent întâlniţi în practica gi­ne­co­lo­gică, motivele prezentării la medic fiind cel mai adesea in­fer­ti­li­tat...

08 martie 2019
STERILITATE | Ediţia 4 18 / 2017

Noi concepte în tratamentul infertilităţii. Quatrefolic® versus acid folic

Cristina Teodorescu, Florentina Gherghiceanu, Silviu Pituru

Apariţia vieţii rămâne un miracol, în timp ce lipsa unui urmaş pentru un cuplu reprezintă o problemă.

18 decembrie 2017
GINECOLOGIE | Ediţia 12 (2) / 2016

Istmocelul - complicaţie a naşterii prin operaţie cezariană

Ciprian Andrei  Coroleucă, Cătălin Bogdan Coroleucă, Costin Berceanu, Conf. Univ. Dr. Mehedintu Claudia

Istmocelul reprezintă un defect al peretelui anterior al istmului uterin şi este localizat la nivelul cicatricei uterine apărute în urma naşterii p...

15 aprilie 2016
STERILITATE | Ediţia 1 15 / 2017

Fenotipurile ovarului micropolichistic şi răspunsul la tehnicile de reproducere umană asistată - Fertilizare in vitro

Lucia Luchian, Dragoș Marinescu

Sindromul ovarelor micropolichistice (OMPC) este afecţiunea endocrinologică cel mai frecvent întâlnită la femeile în pe­rioa­da reproductivă. Ca ur...

20 martie 2017